Eculizumab causes the complement system, a part of your immune system, to be less active. By doing this it reduces hemolysis, the destruction of red blood cells, in patients with PNH. It is in a class of drugs call monoclonal antibodies.
| Clinical Trial | Status | Age Group |
|---|---|---|
| Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | Recruiting | |
| PEGASUS: A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH | Active, not recruiting | 18 years and older |
AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.
